Gene therapy for arterial thrombosis

Cardiovascular Research

Volumn 35, Issue 3, 1997, Pages 459-469

  Vassalli, Giuseppe ^a   Dichek, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; HIRUDIN; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR; PROSTACYCLIN; THROMBIN INHIBITOR; THROMBOMODULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTERY WALL; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FIBRINOLYSIS; GENE EXPRESSION; GENE TRANSFER; HEART INFARCTION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; THROMBOSIS;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; THROMBOSIS; VIRUSES;

EID: 0030856192     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00153-3     Document Type: Review

References (94)

1. Jaffe E. The role of blood vessels in hemostasis. In: Williams WJ, Erslev AJ, Lichtman, MA, eds. Hematology. New York: McGraw-Hill, 1993:1322-1337.
2. Weksler B., Marcus A., Jaffe E. Synthesis of prostaglandin I-2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA. 74:1977;3922-3926.
3. Salem H.H., Maruyama I., Ishii H., Majerus P.W. Isolation and characterization of thrombomodulin from human placenta. J Biol Chem. 259:1984;12246-12251.
4. Levin E. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA. 80:1983;6804-6808.
5. Gimbrone Jr MA. Vascular endothelium: nature's blood container. In: Gimbrone Jr MA, ed. Vascular endothelium in hemostasis and thrombosis. Edinburgh: Churchill Livingstone, 1986:1-13.
6. Erickson L.A., Ginsberg M.H., Loskutoff D.J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 74:1984;1465-1472.
7. Dichek D.A., Anderson J., Kelly A.B., Hanson S.R., Harker L.A. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation. 93:1996;301-309.
8. Esmon C.T. Thrombomodulin as model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 9:1995;946-955.
9. Fisher R., Waller E., Grossi G., Thompson D., Tizard R., Schleuning W. Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5′ flanking region. J Biol Chem. 260:1985;11223-11230.
10. + RNA. Proc Natl Acad Sci USA. 81:1984;4727-4731.
11. Marcus A., Weksler B., Jaffe E., Broekman M. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest. 66:1980;979-986.
12. De Agostini A., Rosenberg R. New approaches for defining the molecular basis of anticoagulantly active heparan sulfate production. Ann NY Acad Sci. 614:1991;279-288.
13. Nabel E. Gene therapy for cardiovascular disease. Circulation. 91:1995;541-548.
14. Lemarchand P., Jones M., Yamada I., Crystal R.G. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res. 72:1993;1132-1138.
15. Schulick A.H., Dong G., Newman K.D., Virmani R., Dichek D.A. Endothelium-specific in vivo gene transfer. Circ Res. 77:1995;475-485.
16. Newman K.D., Dunn P.F., Owens J.W.et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 96:1995;2955-2965.
17. Schneider M.D., French B.A. The advent of adenovirus. Gene therapy for cardiovascular disease. Circulation. 88:1993;1937-1942.
18. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gönczöl E., Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 91:1994;4407-4411.
19. Yang Y., Ertl H.C.J., Wilson J.M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1:1994;433-442.
20. Schulick A.H., Vassalli G., Dunn P.F.et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 99:1997;209-219.
21. Chen H.H., Macl L.M., Kelly R., Ontell M., Kochanek S., Clemens P.R. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA. 94:1997;1645-1650.
22. Nabel E.G., Plautz G., Nabel G.J. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 249:1990;1285-1288.
23. Chapman G.D., Lim C.S., Gammon R.S.et al. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res. 71:1992;27-33.
24. Flugelman M.Y., Jaklitsch M.T., Newman K.D., Casscells W., Bratthauer G.L., Dichek D.A. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation. 85:1992;1110-1117.
25. Steg P.G., Feldman L.J., Scoazec J.-Y.et al. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation. 90:1994;1648-1656.
26. Rios C., Ooboshi H., Piegors D., Davidson B., Heistad D. Adenovirus-mediated gene transfer to normal and atherosclerotic arteries. A novel approach. Arterioscl Thromb Vasc Biol. 15:1995;2241-2245.
27. Nabel E.G., Plautz G., Boyce F.M., Stanley J.C., Nabel G.J. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 244:1989;1342-1344.
28. Dichek D.A., Neville R.F., Zwiebel J.A., Freeman S.M., Leon M.B., Anderson W.F. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation. 80:1989;1347-1353.
29. Isner J.M., Walsh K., Symes J.et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation. 91:1995;2687-2692.
30. Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., Rosenfield K., Razvi S., Walsh K., Symes J.F. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischemic limb. Lancet. 348:1996;370-374.
31. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (Part II). New Engl J Med. 326:1992;310-318.
32. Weaver W., Cerqueira M., Hallstrom A.et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. J Am Med Assoc. 270:1993;1211-1216.
33. French B.A., Mazur W., Ali N.M.et al. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation. 90:1994;2402-2413.
34. Yao S., Ober J., Gonenne A.et al. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res. 73:1993;952-967.
35. Rade J.J., Schulick A.H., Virmani R., Dichek D.A. Local adenoviral-mediated expression of recombinant hirudin reduces neointimal formation after arterial injury. Nature Med. 2:1996;293-298.
36. Lim C.S., Chapman G.D., Gammon R.S.et al. Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog. Circulation. 83:1991;2007-2011.
37. van der Meer J., Hillege H., Dunselman P.et al. Oral anticoagulation in the prevention of one-year vein graft occlusion after aortocoronary bypass surgery: optimal therapeutic range and practical limitations. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Thromb Haemost. 72:1994;676-681.
38. Barry W., Sarembock I. Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty. Cardiol Clin. 12:1994;517-535.
39. Colombo A., Hall P., Nakamura S.et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 91:1995;1676-1688.
40. Albiero R., Hall P., Itoh A.et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlodipine and aspirin therapy. Circulation. 95:1997;1145-1156.
41. Serruys P.W., Emanuelsson H., van der Giessen W.et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation. 93:1996;412-422.
42. van der Giessen W., Serruys P., Visser W., Verdouw P., van Schalkwijk W., Jongkind J. Endothelialization of intravascular stents. J Intervent Cardiol. 1:1988;109-120.
43. Flugelman M., Dichek D.A. Seeding of intracoronary stents with endothelial cells: current status and future prospects. J Intervent Cardiol. 4:1995;383-385.
44. Zoldhelyi P., McNatt J., Xu X.-M.et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 93:1996;10-17.
45. Willard J.E., Landau C., Glamann D.B.et al. Genetic modification of the vessel wall. Comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation. 89:1994;2190-2197.
46. Ooboshi H., Welsh M., Rios C., Davidson B., Heistad D. Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue. Circ Res. 77:1995;7-13.
47. Schachtner S.K., Rome J.J., Hoyt R.F. Jr., Newman K.D., Virmani R., Dichek D.A. In vivo adenovirus-mediated gene transfer via the pulmonary artery of rats. Circ Res. 76:1995;701-709.
48. The Duration of Anticoagulation Trial Study Group, Schulman S., Granqvist S., Holmstrom M.et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. New Engl J Med. 336:1997;393-398.
49. Rutherford R, Nishikimi N. Graft thrombosis and thromboembolic complications. In: Rutherford R, ed. Vascular surgery. Philadelphia, PA: WB Saunders Co, 1989:501-510.
50. Williams S. Endothelial cell transplantation. Cell Transplant. 4:1995;401-410.
51. Clowes A. Improving the interface between biomaterials and the blood. The gene therapy approach. Circulation. 93:1996;1319-1320.
52. Zilla P., Deutsch M., Meinhart J.et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg. 19:1994;540-548.
53. Oertenwall P., Wadenvik H., Kutti J., Risberg B. Endothelial cell seeding reduces thrombogenicity of Dacron grafts in humans. J Vasc Surg. 11:1990;403-410.
54. Herring M., Smith J., Dalsing M.et al. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: the failure of low-density seeding to improve patency. J Vasc Surg. 20:1994;650-655.
55. Moncada S., Vane J.R. Biological significance and therapeutic potential of prostacyclin. J Med Chem. 23:1980;591-593.
56. Szczeklik A., Nizankowski R., Skawinski S., Szczeklik J., Gluszko P., Gryglewski R. Successful therapy of advanced atherosclerosis obliterans with prostacyclin. Lancet. 1:1979;1111-1114.
57. Belch J., Newman P., Drury J.et al. Intermittent prostacyclin infusion in patients with Raynaud's syndrome. Lancet. 1:1983;313-315.
58. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. New Engl J Med. 329:1993;2002-2012.
59. Chronos N., Lundell A., Harker L., Hanson S. Inhibition of platelet dependent thrombosis by a novel nitric oxide releasing agent delivered locally in a baboon A-V shunt. Circulation. 94(Suppl.):1996;I-696. Abstract.
60. Yan Z., Yokota T., Zhang W., Hansson G. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res. 79:1996;38-44.
61. von der Leyen H.E., Gibbons G.H., Morishita R.et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1995;1137-1141.
62. Flaherty D., Zengxuan N., Van Pelt N., Zoldhelyi P., Gerard R.D., Collen D. Overexpression of human constitutive nitric oxide synthase gene reduces neointima formation in balloon-injured rat carotid arteries. Circulation. 94(Suppl.):1996;I-590. Abstract.
63. Nong Z., Flaherty D., Hoylaerts M., Collen D., Janssens S. Single aerosol delivery of human constitutive nitric oxide synthase gene inhibits platelet aggregation and reduces neointima formation in injured rat carotid arteries. Circulation. 94(Suppl.):1996;I-590. Abstract.
64. Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol. 19:1970;924-932.
65. Blombäck B. Studies on the action of thrombic enzymes on bovine fibrinogen as measured by N-terminal analysis. Arkiv Kemi. 12:1958;321-335.
66. Davey M.G., Lüscher E.F. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature. 216:1967;857-858.
67. McNamara C.A., Sarembock I.J., Gimple L.W., Fenton J.W. II, Coughlin S.R., Owens G.K. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 91:1993;94-98.
68. Just M., Tripier D., Seiffge D. Antithrombotic effects of recombinant hirudin in different animal models. Haemostasis. 21(Suppl. 1):1991;80-87.
69. Sarembock I.J., Gertz S.D., Gimple L.W., Owen R.M., Powers E.R., Roberts W.C. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 84:1991;232-243.
70. Topol E.J., Fuster V., Harrington R.A.et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation. 89:1994;1557-1566.
71. Serruys P.W., Herrman J.-P.R., Simon R. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. New Engl J Med. 333:1995;757-763.
72. van den Bos A.A., Deckers J.W., Heyndrickx G.R.et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 88:1993;2058-2066.
73. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 90:1994;1631-1637.
74. Kottke-Marchant K., Zoldhelyi P., Zamaro C., Brooks L., Cianciolo C., Janssens S. The effect of deshirudin vs. heparin on hemostatic parameters in acute coronary syndromes: the GUSTO IIb hemostasis substudy. Circulation. 94(Suppl.):1996;I-742. Abstract.
75. Watkins M., Luetmer P., Witmer W., Vaitkus P., Schneider D., Sobel B. Rebound generation of thrombin after coronary interventions: a potential contributor to subacute thrombosis. Circulation. 94(Suppl.):1996;I-375. Abstract.
76. Esmon C. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost. 70:1993;29-35.
77. Stearns-Kurosawa D., Kurosawa S., Mollica J., Ferrell G., Esmon C. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA. 93:1996;10212-10216.
78. Kupfer J., Lei W., Pan T. Adenovirus-mediated gene transfer of thrombomodulin to human endothelial cells: effects on thromboresistance and in-vitro clotting. Circulation. 94(Suppl.):1996;I-741. Abstract.
79. Broze G.J. Tissue factor pathway inhibitor. Thromb Haemost. 74:1995;90-93.
80. Brown D., Kania N., Choi E.et al. Local irrigation with tissue factor pathway inhibitor inhibits intimal hyperplasia induced by arterial interventions. Arch Surg. 131:1996;1086-1090.
81. Wang Z., Hebert D., Kaplan A., Creasy A., Galluppi G. Persistent inhibition to 12 hours of mural platelet thrombosis after a single local infusion of tissue factor pathway inhibitor at the site of angioplasty. Circulation. 94(Suppl.):1996;I-268. Abstract.
82. Hauptmann J., Kaiser B. Anticoagulant and antithrombotic action of the factor Xa inhibitor antistasin (ATS). Thromb Res. 71:1993;169-174.
83. Gasic G., Arenas C., Gasic T., Gasic G. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA. 89:1992;2317-2320.
84. Ragosta M., Gimple L., Gertz S.et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 89:1994;1262-1271.
85. Schaffer L., Davidson J., Vlasuk G., Dunwiddie C., Siegl P. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscl Thromb. 12:1992;879-885.
86. Mellott M., Holahan M., Lynch J., Vlasuk G., Dunwiddie C. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res. 70:1992;1152-1160.
87. Levin E., del Zoppo G. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol. 144:1994;855-861.
88. Dichek D., Quertermous T. Variability in messenger RNA levels in human umbilical vein endothelial cells of different lineage and time in culture. In Vitro Cell Dev Biol. 25:1989;289-292.
89. Podrazik R., Whitehill T., Ekhterae D., Williams W., Messina L., Stanley J. High-level expression of recombinant human tPA in cultivated canine endothelial cells under varying conditions of retroviral gene transfer. Ann Surg. 216:1992;446-452.
90. Sawdey M.S., Loskutoff D.J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β J Clin Invest. 88:1991;1346-1353.
91. Lee S.W., Kahn M.L., Dichek D.A. Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. J Biol Chem. 267:1992;13020-13027.
92. Plow E., Felez J., Miles L. Cellular regulation of fibrinolysis. Thromb Haemost. 66:1991;32-36.
93. Lee S.W., Ellis V., Dichek D.A. Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. J Biol Chem. 269:1994;2411-2418.
94. Dunn P.F., Newman K.D., Jones M.et al. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation. 93:1996;1439-1446.